Option chain shows key data for Prosegur Cash's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Prosegur Cash.

Prosegur Cash (OTC:PGUCY) Stock, Option Chain

Prosegur Cash SA is engaged in the transit business and the outsourcing of services to financial institutions, retail establishments, government agencies and central banks, national mints, jewelers and other business activities around the world. The company's business lines can be categorized into Transport, Cash management, and New Products such as Automation of payments in shops using self-service cash machines, among others. The Business Divisions of the company are divided into three geographical segments: Europe, Asia-Oceania-Africa (AOA) and LatAm. The majority of the revenue is generated from the LatAm segment.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AAWW

ABMD

ACRGF

ACTG

ADAP

AERO

AEZS

AGGZF

AKKVF

ALBO

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALKS

ALPN

ALXEF

ANDE

ANGI

ARHN

ARLP

Adtalem Global Education Inc. Common Stock

ATGE

AUPH

AWSM

AXAS

AXDDF

BCRX

BCTXF

BIEI

BLOZF

BLOK TECHNOLOGIES INC by Blok Technologies Inc.

BLPFF

BOIVF

BOSSY

BOTY

BRTX

BSTC

BTLLF

CEIX

CERS

CGNSF

CHKDG

CHKDP

CHOOF

CKISF

CLDPQ

CLVS

CMCT

CMRX

CMVLF

CNONF

CNSL

COTE

CRBP

CRZBY

CSLT

CTMX

CTST

CVEO

CWRK

CYIG

DFIN

DIIBF

DKAM

DNOW

DZSI

EBKDY

ECIFY

EMESQ

ENBL

EZPW

FANG

FELP

FENG

FLMN

FRHLF

FRLI

FRNKF

FSNNQ

FTCH

FTSI

FTSV

FULC

GAIA

GARB

GARLF

GDOT

Stocks That Hit 52-Week Lows On Tuesday

Prosegur Cash SA

Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.11 by 72.73 percent. This is a 160 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $188.31 million which beat the analyst consensus estimate of $183.00 million by 2.90 percent. This is a 16.58 percent increase over sales of $161.53 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Marcus Q4 2024 GAAP EPS $0.03 Misses $0.11 Estimate, Sales $188.31M Beat $183.00M Estimate

Rosenblatt analyst Steven Frankel maintains Xperi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPER#NYSE">XPER</a>) with a Buy and maintains $15 price target.

Price Target

Analyst Ratings

XPER

Rosenblatt Maintains Buy on Xperi, Maintains $15 Price Target

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.03) by 166.67 percent. This is a 128.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $40.78 million which beat the analyst consensus estimate of $37.37 million by 9.14 percent. This is a 19.13 percent increase over sales of $34.23 million the same period last year.

HRTX

Heron Therapeutics Q4 2024 GAAP EPS $0.02 Beats $(0.03) Estimate, Sales $40.78M Beat $37.37M Estimate

Guidance

TGNA

TEGNA Sees Q1 Revenue Decline Of (-4%) - (-7%)

Baird analyst Jeff Johnson maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Neutral and lowers the price target from $37 to $33.

TNDM

Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $33

TEGNA Sees FY25 Free Cash Flow Of $900M - $1.1B; Capital Expenditure Of $50M - $60M

Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) with a Outperform and raises the price target from $50 to $55.

MIRM

Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $55

The study is expected to randomize thirty-six (36) patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi&nbsp;(CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD).
 &nbsp;

MDCX

Medicus Pharma Submits Clinical Design (SKNJCT-004) To UAE DOH To Non-Invasively Treat BCC Of The Skin

Rosenblatt analyst Blair Abernethy maintains Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Buy and maintains $660 price target.

SNPS

Rosenblatt Maintains Buy on Synopsys, Maintains $660 Price Target

Baird analyst Joel Beatty maintains Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) with a Neutral and lowers the price target from $10 to $8.

COGT

Baird Maintains Neutral on Cogent Biosciences, Lowers Price Target to $8

Health Care

Stock Split

VERO

Venus Concept Will Effect A 1-for-11 Reverse Stock Split, Effective At 5:00 P.M. Eastern Standard Time On March 3

Needham analyst David Saxon reiterates ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) with a Buy and maintains $23 price target.

Reiteration

ZIMV

Needham Reiterates Buy on ZimVie, Maintains $23 Price Target

Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(0.99) by 11.11 percent. This is a 19.27 percent increase over losses of $(1.09) per share from the same period last year.

Dyne Therapeutics Q4 2024 GAAP EPS $(0.88) Beats $(0.99) Estimate

Baird analyst Jeff Johnson maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Outperform and raises the price target from $104 to $108.

Baird Maintains Outperform on Alcon, Raises Price Target to $108

Cars.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARS#NYSE">CARS</a>) reported quarterly earnings of $0.49 per share which missed the analyst consensus estimate of $0.56 by 12.5 percent. This is a 2.08 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $180.43 million which missed the analyst consensus estimate of $183.90 million by 1.88 percent. This is a 0.46 percent increase over sales of $179.61 million the same period last year.

CARS

CORRECTION: Cars.com Q4 Adj EPS $0.49 Misses $0.56 Estimate, Sales $180.43M Miss $183.90M Estimate

Tegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGNA#NYSE">TGNA</a>) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.16 by 4.31 percent. This is a 181.4 percent increase over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $870.53 million which missed the analyst consensus estimate of $870.79 million by 0.03 percent. This is a 19.93 percent increase over sales of $725.85 million the same period last year.

Tegna Q4 Adj $1.21 Beats $1.16 Estimate, Sales $870.53M Miss $870.79M Estimate

Rosenblatt analyst Blair Abernethy maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and maintains $205 price target.

SNOW

Rosenblatt Maintains Buy on Snowflake, Maintains $205 Price Target

Baird analyst Eric Coldwell maintains AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) with a Outperform and raises the price target from $14 to $16.

AHCO

Baird Maintains Outperform on AdaptHealth, Raises Price Target to $16

THRY

Thryv Sees Q1 SaaS Revenue Of $107.5M - $110.0M; SaaS Adjusted EBITDA Of $9.0M - $9.5M

Baird analyst Catherine Schulte maintains Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) with a Outperform and lowers the price target from $161 to $159.

Baird Maintains Outperform on Agilent Technologies, Lowers Price Target to $159

Prosegur Cash

Comments

Prosegur Cash

Prosegur Cash (PGUCY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga